Biotechnology Value Fund L P's Form 4 filing
Repare Therapeutics Inc. (RPTX) · filed Jun 15, 2022
- Accession no.
- 0000921895-22-002007
- Filed
- Jun 15, 2022, 6:15 PM ET
- Trade date
- Jun 13, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $1.90M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Biotechnology Value Fund L PCIK 0000918923 | 10% Owner |
| BVF Partners L PCIK 0001055947 | 10% Owner |
| BVF IncCIK 0001056807 | 10% Owner |
| Biotechnology Value Fund II LPCIK 0001102444 | Other: See Explanation of Responses |
| Lampert Mark NCIK 0001233840 | 10% Owner |
| Biotechnology Value Trading Fund OS LPCIK 0001660683 | Other: See Explanation of Responses |
| BVF Partners OS Ltd.CIK 0001660684 | Other: See Explanation of Responses |
| BVF I GP LLCCIK 0001803805 | 10% Owner |
| BVF II GP LLCCIK 0001803806 | Other: See Explanation of Responses |
| BVF GP Holdings LLCCIK 0001803809 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 13, 2022 | Common Shares, no par value | PPurchaseAcquired | +74,666 | $12.73 | +$950,498.18 | 4,443,423 | Direct | |
| Jun 13, 2022 | Common Shares, no par value | PPurchaseAcquired | +68,327 | $12.73 | +$869,802.71 | 3,299,906 | Direct | |
| Jun 13, 2022 | Common Shares, no par value | PPurchaseAcquired | +6,168 | $12.73 | +$78,518.64 | 412,604 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.